Basic Cancer Info

We are in the midst of a remarkable transitional time in cancer care that is exciting but challenging, since we now have patients divided into smaller and smaller groups based on molecular markers.  Along with that, more and more patients and caregivers are participating in social media and online discussion groups.  What are the implications for these changes, and how can we use them to accelerate the pace of clinical research?  I'd like to focus on a couple of key questions for our next lung cancer tweetchat on September 26, at 8 PM Eastern, 5 PM Pacific.

Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.

[powerpress]

Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor ganetespib combined with combined with second line docetaxel in advanced lung adenocarcinoma.

[powerpress]

Dr. Edward Garon, David Geffen School of Medicine at UCLA, discusses results in a trial that demonstrated a significant survival benefit with nintedanib combined with second line docetaxel in advanced lung adenocarcinoma.

[powerpress]

Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.

[powerpress]

The concept of "over-treatment" of lung cancer may sound heretical to some here, as it is unquestionably a fearsome cancer. Nevertheless, it's important to recognize that cancers can range from quite indolent to virulently aggressive and that some forms may be so minimally threatening that treatment may be worse than the disease.

Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of predictive biomarkers ERCC1 and RRM1 in advanced NSCLC.

[powerpress]

Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews the landmark Biomarkers France study that tested a wide range of molecular markers in NSCLC.

[powerpress]

Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC.

[powerpress]

Dr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit of chemo or EGFR inhibitor for second line treatment of advanced lung cancer.

[powerpress]